View on Pubmed.gov 16831079 | View on doi.org 10.1586/1473714...
Chemotherapy resistance in osteosarcoma: current challenges and future directions.
- Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. choua@mskcc.org
Abstract
For patients with osteosarcoma, the use of chemotherapy has improved survival from 11% with surgical resection alone in the 1960s, to 70% by the mid-1980s. However, survival has since plateaued, despite advances in anticancer therapy. Elucidation of the mechanisms of chemoresistance and implementation of strategies to overcome chemoresistance will likely be pivotal to improving survival. In this review, the focus is on the current understanding of the mechanisms of resistance to the most commonly used agents in the treatment of osteosarcoma and the methods employed to overcome chemotherapy resistance.
References
Cited by 368 citations (total)
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't
Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism.
Electronic publication date February 27, 2009
Xin Zheng [...] Abdelhadi Rebbaa et al.
Cathepsin L is a lysosomal enzyme thought to play a key role in malignant transformation. Recent work from our laboratory...
Journal Article Review
Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy.
Electronic publication date October 22, 2008
Akio Sakamoto [...] Yukihide Iwamoto et al.
Osteosarcoma is the most common primary bone tumor in childhood and adolescence. The use of combination chemotherapy and surgery enables...
Conflict of interest statement
MeSH
- •
- •
- •
Specialties
- •
- •